**Company Profile**

**Industry Sector:** Biotechnology

**Company Overview:** Glycan Therapeutics was founded in 2013 and is located in Chapel Hill, NC. The company is a spin out from UNC Chapel Hill. Glycan is a pioneer in the synthesis of structurally defined heparan sulfate and heparin oligosaccharides for glycobiology researchers using a new patented chemoenzymatic technology.

**Target Market(s):**
- Academic and Industry research laboratories.
- Anticoagulants, cancer, anti-infectives and diagnostic markers.

**Key Value Drivers**

**Technology**: A platform technology using chemoenzymatic synthesis of heparin and heparin like compounds. It is very cost efficient by significantly reducing the steps required compared to chemical synthesis.

**Competitive Advantage**: We can produce high purity products that are cheaper than chemical synthetic methods suitable for research and drug development. The process is versatile and scalable.

**Plan & Strategy**: Sell oligosaccharide library compounds and perform custom synthesis of heparan sulfate compounds.
- Develop synthetic heparin and other biotherapeutics based on heparan sulfates.

**Management**

**Leadership:**
Jian Liu, Ph.D. - Founder and Chief Scientific Officer
Jian is a Distinguished Professor at UNC-CH and has spent more than 25 years working with heparin. He is the inventor of the enzyme-based method to prepare heparan sulfate compounds.

Jim Peterson, Ph.D, MBA - Chief Operating Officer
Jim started his career as Group Leader at Sterling Drug and has an additional 25 years experience in research administration and research consulting and business consulting.

**Product Pipeline**

1. **Pipeline One**: The company offers a catalogue of 24 homogeneous heparan sulfate oligosaccharides with 39 additional compounds in June 2016.

2. **Pipeline Two**: Glycan can synthesize heparan sulfate oligosaccharides with unprecedented structural complexity and also offers custom synthesis of oligosaccharides with different sizes, sulfation, and purity up to 18-mers.

3. **Pipeline Three**: Develop carbohydrate based medicines including synthetic Heparin, cancer, anti-infectives and diagnostic markers.